Sun Pharma’s June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.
Is the smallcap rally a trap? Only 37% of stocks are outperforming their benchmark
India’s recent smallcap surge indicates that less stock is outpacing the benchmark index, revealing a narrowing group of successful stocks boosting overall returns. Conversely, largecap
August 25, 2026